Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdAPT-001
- Development stage
- Phase 2
- Lead developer
- EpicentRx
- Modality
- Gene Silencing → Gene Therapies, Oncolytic Viruses → Oncolytic Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
- Administration
- Intratumoral, Intraarterial
01
Overview
AdAPT-001 is an investigational oncolytic virus therapy based on a replication-competent type 5 adenovirus engineered to express a transforming growth factor beta (TGF-β) receptor-immunoglobulin fusion protein ("TGF-β trap"). This design enables the virus to selectively infect and lyse tumor cells while locally neutralizing the immunosuppressive and profibrotic cytokine TGF-β within the tumor microenvironment. By inhibiting TGF-β signaling, AdAPT-001 aims to enhance antitumor immune responses and overcome resistance to immune checkpoint inhibitors. The drug is being developed primarily for solid tumors such as soft tissue sarcoma and chondrosarcoma. It can be administered via intratumoral or intraarterial injection[1][3][4][6].
- Other names
- TGF-beta trap adenovirusTGF-β trap
02
Targets
TGFB3 (Transforming growth factor beta 3)TGFB1 (Transforming growth factor Beta-1 proprotein)
Beyond the preview
Go deeper on AdAPT-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdAPT-001.